SCHEMBL10073219

SCHEMBL10073219

COC(=O)c1c(C)cc(-c2cc[n+]([O-])cc2)cc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.44
ACHE P22303 1/20 0.44
HPGD P15428 2/20 0.41
MAPT P10636 1/20 0.41
POLB P06746 2/20 0.38
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA7 P43166 1/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.36
LMNA P02545 1/20 0.36
ABL1 P00519 1/20 0.35
RIN1 Q13671 1/20 0.35
CASP1 P29466 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL598248 0.81 CYP3A4 (0.39) CYP3A4ACHEHPGDMAPTKDM4E
SCHEMBL10073220 0.77 CYP46A1 (0.53) CYP3A4ACHEHPGDPOLBCA12
SCHEMBL743734 0.76 CA1 (0.57) MAPTCA12CA1CA2CA9
SCHEMBL7746141 0.75 PDE1A (0.48)
SCHEMBL1780723 0.71 MAPT (0.63) MAPTCA12CA1CA2CA9
SCHEMBL17459525 0.71 HTT (0.55) CYP3A4ACHEHPGDMAPTKDM4E
SCHEMBL4809404 0.71 MAPT (0.49) CYP3A4ACHEHPGDMAPTKDM4E
SCHEMBL1036031 0.70 CYP3A4 (0.59) CYP3A4ACHEHPGDMAPTPOLB
SCHEMBL3196624 0.70 HSD17B10 (0.47) CYP3A4ACHEHPGDMAPTCA12
SCHEMBL70139 0.69 CYP3A4 (0.57) CYP3A4ACHEHPGDMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114879-B2 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides SCHERING CORPORATION (US) 2012-02-14 US disclosed
US-7825121-B2 Piperazine derivatives useful as CCR5 antagonists SCHERING CORPORATION (US) 2010-11-02 US disclosed
US-7825121-B2 Piperazine derivatives useful as CCR5 antagonists SCHERING CORPORATION (US) 2010-11-02 US disclosed
US-20080188485-A1 PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS SCHERING CORPORATION 2008-08-07 US disclosed
US-7384944-B2 Piperazine derivatives useful as CCR5 antagonists SCHERING CORPORATION (US) 2008-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188485-A1 PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS CCR5, CXCR3, CCR2 CYP3A4 792/4885ACHE 3742/4885HPGD 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.